重组人干扰素α-1b雾化吸入治疗小儿毛细支气管炎的临床效果
|
摘要
目的:观察重组人干扰素α-1b雾化吸入治疗小儿毛细支气管炎的临床效果。方法:选择2017年3月至2018年3月毛细支气管炎患儿80例,按照随机数字表法分为对照组和观察组各40例,对照组采用热毒宁治疗,观察组采用重组人干扰素α-1b雾化吸入方案治疗,比较两组治疗后总有效率、症状体征消失时间、潮气呼吸肺功能指标、炎症指标和不良反应率。结果:观察组治疗总有效率为97.5%,高于对照组的82.5%,差异有统计学意义(P<0.05);观察组肺部啰音、喘憋、三凹症、哮鸣音、咳嗽症状体征消失时间短于对照组,差异有统计学意义(P<0.05);治疗后,观察组肺功能指标FVC、FEV1高于对照组,IL-4水平明显低于对照组,IL-10水平明显高于对照组,差异均有统计学意义(P<0.05);两组不良反应率比较,差异无统计学意义(P>0.05)。结论:重组人干扰素α-1b雾化吸入治疗小儿毛细支气管炎的临床效果优于热毒宁的治疗效果。
Objective: To observe clinical effects of recombinant human interferon α-1 b aerosol inhalation in treatment of childrenwith bronchiolitis. Methods: 80 children with bronchiolitis admitted to our hospital from March 2017 to March 2018 were selected and randomlydivided into control group(n=40) and observation group(n=40). The control group was treated with Reduning, while the observation group wasgiven recombinant human interferon α-1 b aerosol inhalation. The total effective rate, symptom and sign disappearance time, tidal respiratory lungfunction indexes, inflammation indexes and adverse reaction rate were compared between the two groups. Results: The total effective rate of theobservation group was 97.5%, which was higher than that of the control group(82.5%), and the difference was statistically significant(P<0.05). Thedisappearance time of lung rales, wheezing, three concave sign, wheezes, cough symptoms and signs of the observation group was shorter than thatof the control group, and the difference was statistically significant(P<0.05). After the treatment, the pulmonary function indexes FVC and FEV1 levels of the observation group were higher than those of the control group, the IL-4 level was significantly lower than that of the control group, theIL-10 level was significantly higher than that of the control group, and the differences were statistically significant(P<0.05). However, there were nosignificant differences in the adverse reactiona rate between the two groups(P>0.05). Conclusions: Recombinant human interferon α-1 b inhalation inthe treatment of the children with bronchiolitis is superior to Reduning.
Objective: To observe clinical effects of recombinant human interferon α-1 b aerosol inhalation in treatment of childrenwith bronchiolitis. Methods: 80 children with bronchiolitis admitted to our hospital from March 2017 to March 2018 were selected and randomlydivided into control group(n=40) and observation group(n=40). The control group was treated with Reduning, while the observation group wasgiven recombinant human interferon α-1 b aerosol inhalation. The total effective rate, symptom and sign disappearance time, tidal respiratory lungfunction indexes, inflammation indexes and adverse reaction rate were compared between the two groups. Results: The total effective rate of theobservation group was 97.5%, which was higher than that of the control group(82.5%), and the difference was statistically significant(P<0.05). Thedisappearance time of lung rales, wheezing, three concave sign, wheezes, cough symptoms and signs of the observation group was shorter than thatof the control group, and the difference was statistically significant(P<0.05). After the treatment, the pulmonary function indexes FVC and FEV1 levels of the observation group were higher than those of the control group, the IL-4 level was significantly lower than that of the control group, theIL-10 level was significantly higher than that of the control group, and the differences were statistically significant(P<0.05). However, there were nosignificant differences in the adverse reactiona rate between the two groups(P>0.05). Conclusions: Recombinant human interferon α-1 b inhalation inthe treatment of the children with bronchiolitis is superior to Reduning.
引文
[1]尚云晓,黄英,刘恩梅,等.雾化吸入重组人干扰素α1b治疗小儿急性毛细支气管炎多中心研究[J].中国实用儿科杂志,2014,29(11):840-844.
[2]晁占湖,闫怀莲,秦凌阳.雾化吸入不同剂量重组人干扰素α-1b治疗小儿毛细支气管炎临床分析[J].医药前沿,2016,6(18):121-122.
[3]廖洪彬.雾化吸入重组人干扰素α1b治疗小儿毛细支气管炎的安全性和疗效分析[J].临床医学工程,2016,23(4):485-486.
[4]胡亚美,江载芳,诸褔棠.诸褔棠实用儿科学[M]. 7版.北京:人民卫生出版社,2013:1199-1202.
[5]许静,周旭红,邓全敏.雾化吸入不同剂量重组人干扰素α1b治疗小儿急性毛细支气管炎的疗效比较[J].海南医学,2017,28(13):2116-2118.
[6]周何龙.重组人干扰素α1b雾化吸入治疗急性毛细支气管炎患儿临床疗效观察[J].临床医学研究与实践,2016,1(26):41-46.
[7]陈玲,覃军,胡荆江.重组人干扰素α1b雾化吸入在急性毛细支气管炎患儿中的应用价值分析[J].临床肺科杂志,2016,21(8):1435-1438.
[8]黄云.不同剂量干扰素α1b雾化治疗小儿毛细支气管炎疗效及安全性[J].儿科学杂志,2015,21(8):25-27.
[9]刘李辉.重组人干扰素α1b对小儿急性毛细支气管炎的治疗效果[J].实用中西医结合杂志,2017,17(8):137-138.
[10]张跃川.压缩泵雾化吸入重组人干扰素α-1b治疗毛细支气管炎的临床观察[J].中国医药指南,2016,14(8):167.
[2]晁占湖,闫怀莲,秦凌阳.雾化吸入不同剂量重组人干扰素α-1b治疗小儿毛细支气管炎临床分析[J].医药前沿,2016,6(18):121-122.
[3]廖洪彬.雾化吸入重组人干扰素α1b治疗小儿毛细支气管炎的安全性和疗效分析[J].临床医学工程,2016,23(4):485-486.
[4]胡亚美,江载芳,诸褔棠.诸褔棠实用儿科学[M]. 7版.北京:人民卫生出版社,2013:1199-1202.
[5]许静,周旭红,邓全敏.雾化吸入不同剂量重组人干扰素α1b治疗小儿急性毛细支气管炎的疗效比较[J].海南医学,2017,28(13):2116-2118.
[6]周何龙.重组人干扰素α1b雾化吸入治疗急性毛细支气管炎患儿临床疗效观察[J].临床医学研究与实践,2016,1(26):41-46.
[7]陈玲,覃军,胡荆江.重组人干扰素α1b雾化吸入在急性毛细支气管炎患儿中的应用价值分析[J].临床肺科杂志,2016,21(8):1435-1438.
[8]黄云.不同剂量干扰素α1b雾化治疗小儿毛细支气管炎疗效及安全性[J].儿科学杂志,2015,21(8):25-27.
[9]刘李辉.重组人干扰素α1b对小儿急性毛细支气管炎的治疗效果[J].实用中西医结合杂志,2017,17(8):137-138.
[10]张跃川.压缩泵雾化吸入重组人干扰素α-1b治疗毛细支气管炎的临床观察[J].中国医药指南,2016,14(8):167.